- call +1-201-465-4211
- email sales@mrinsights.biz
Scope of the Report:
The global Age-Related Macular Degeneration (AMD) Therapeutics market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Age-Related Macular Degeneration (AMD) Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Age-Related Macular Degeneration (AMD) Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Age-Related Macular Degeneration (AMD) Therapeutics market by product type and applications/end industries.
Market Segment by Companies, this report covers
Amgen Inc.
Novartis AG
Bausch Health Companies, Inc.
F. Hoffmann-La Roche Ltd.
Regeneron Pharmaceuticals Inc.
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Wet AMD
Dry AMD
Market Segment by Applications, can be divided into
Hospital
Clinic
Research Institute
Other
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Age-Related Macular Degeneration (AMD) Therapeutics Market Overview
1.1 Product Overview and Scope of Age-Related Macular Degeneration (AMD) Therapeutics
1.2 Classification of Age-Related Macular Degeneration (AMD) Therapeutics by Types
1.2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Comparison by Types (2019-2024)
1.2.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Types in 2018
1.2.3 Wet AMD
1.2.4 Dry AMD
1.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Market by Application
1.3.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Market Share Comparison by Applications (2014-2024)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Research Institute
1.3.5 Other
1.4 Global Age-Related Macular Degeneration (AMD) Therapeutics Market by Regions
1.4.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size (Million USD) Comparison by Regions (2014-2024)
1.4.1 North America (USA, Canada and Mexico) Age-Related Macular Degeneration (AMD) Therapeutics Status and Prospect (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Age-Related Macular Degeneration (AMD) Therapeutics Status and Prospect (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Age-Related Macular Degeneration (AMD) Therapeutics Status and Prospect (2014-2024)
1.4.4 South America (Brazil, Argentina, Colombia) Age-Related Macular Degeneration (AMD) Therapeutics Status and Prospect (2014-2024)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Age-Related Macular Degeneration (AMD) Therapeutics Status and Prospect (2014-2024)
1.5 Global Market Size of Age-Related Macular Degeneration (AMD) Therapeutics (2014-2024)
2 Company Profiles
2.1 Amgen Inc.
2.1.1 Business Overview
2.1.2 Age-Related Macular Degeneration (AMD) Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
2.2 Novartis AG
2.2.1 Business Overview
2.2.2 Age-Related Macular Degeneration (AMD) Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
2.3 Bausch Health Companies, Inc.
2.3.1 Business Overview
2.3.2 Age-Related Macular Degeneration (AMD) Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
2.4 F. Hoffmann-La Roche Ltd.
2.4.1 Business Overview
2.4.2 Age-Related Macular Degeneration (AMD) Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
2.5 Regeneron Pharmaceuticals Inc.
2.5.1 Business Overview
2.5.2 Age-Related Macular Degeneration (AMD) Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2017-2018)
3 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Competition, by Players
3.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Share by Players (2014-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 Age-Related Macular Degeneration (AMD) Therapeutics Players Market Share
3.2.2 Top 10 Age-Related Macular Degeneration (AMD) Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Regions
4.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Market Share by Regions
4.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
4.3 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
4.4 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
4.5 South America Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
4.6 Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
5 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Countries
5.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Countries (2014-2019)
5.2 USA Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
5.3 Canada Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
5.4 Mexico Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
6 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Countries
6.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Countries (2014-2019)
6.2 Germany Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
6.3 UK Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
6.4 France Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
6.5 Russia Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
6.6 Italy Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
7 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Countries
7.1 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Countries (2014-2019)
7.2 China Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
7.3 Japan Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
7.4 Korea Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
7.5 India Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
7.6 Southeast Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
8 South America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Countries
8.1 South America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Countries (2014-2019)
8.2 Brazil Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
8.3 Argentina Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
8.4 Colombia Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
9 Middle East and Africa Revenue Age-Related Macular Degeneration (AMD) Therapeutics by Countries
9.1 Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Countries (2014-2019)
9.2 Saudi Arabia Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
9.3 UAE Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
9.4 Egypt Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
9.5 Nigeria Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
9.6 South Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2014-2019)
10 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Segment by Type
10.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Market Share by Type (2014-2019)
10.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast by Type (2019-2024)
10.3 Wet AMD Revenue Growth Rate (2014-2024)
10.4 Dry AMD Revenue Growth Rate (2014-2024)
11 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Segment by Application
11.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Application (2014-2019)
11.2 Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2014-2019)
11.4 Clinic Revenue Growth (2014-2019)
11.5 Research Institute Revenue Growth (2014-2019)
11.6 Other Revenue Growth (2014-2019)
12 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Forecast (2019-2024)
12.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Forecast (2019-2024)
12.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast by Regions (2019-2024)
12.3 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Forecast (2019-2024)
12.4 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Forecast (2019-2024)
12.5 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Forecast (2019-2024)
12.6 South America Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Forecast (2019-2024)
12.7 Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Forecast (2019-2024)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Age-Related Macular Degeneration (AMD) Therapeutics Picture
Table Product Specifications of Age-Related Macular Degeneration (AMD) Therapeutics
Table Global Age-Rela
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
